| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/20/2006 | WO2006076587A2 Peptides for delivery of mucosal vaccines |
| 07/20/2006 | WO2006076525A2 Combination cancer therapy with anti-psma antibodies |
| 07/20/2006 | WO2006076519A2 Mycobacterial mutants affecting host apoptosis |
| 07/20/2006 | WO2006076517A1 Attenuated mycobacteria as vectors for gene delivery to mammalian cells |
| 07/20/2006 | WO2006076508A2 Method for producing a vaccine for the treatment of cancer |
| 07/20/2006 | WO2006076480A2 Tergeted apheresis for the treatment of rheumaoid arthritis |
| 07/20/2006 | WO2006076467A2 Treatment of pre-eclampsia in pregnant women using targeted apheresis |
| 07/20/2006 | WO2006076417A1 Method for making targeted therapeutic agents |
| 07/20/2006 | WO2006076410A2 Li-key/antigenic epitope hybrid peptide vaccines |
| 07/20/2006 | WO2006076383A2 Composition and method for inducing a protective vaccine response |
| 07/20/2006 | WO2006076343A1 Mycobacteria expressing hiv-1 and malaria antigens |
| 07/20/2006 | WO2006076285A2 Adhesin as immunogen against escherichia coli |
| 07/20/2006 | WO2006076058A1 Method of treating staphylococcus aureus infection |
| 07/20/2006 | WO2006076003A2 Vaccinia virus strains |
| 07/20/2006 | WO2006075784A1 ANTI-α9 INTEGRIN ANTIBODY AND THE USE THEREOF |
| 07/20/2006 | WO2006075668A1 STABILIZED HUMAN IgG1 AND IgG3 ANTIBODIES |
| 07/20/2006 | WO2006075170A1 Meningococcal conjugate vaccination |
| 07/20/2006 | WO2006074914A2 Human rna helicase and therapeutic uses thereof |
| 07/20/2006 | WO2006074891A2 Proteins containing regulatory t-cells for the therapy and diagnosis of illnesses |
| 07/20/2006 | WO2006060419A9 Biomarkers for pre-selection of patients for anti-igf1r therapy |
| 07/20/2006 | WO2006052900A3 Targeted innate immunity |
| 07/20/2006 | WO2006051333A3 Leucine-rich repeat (lrr) motif containing proteins |
| 07/20/2006 | WO2006051069A3 Defective influenza virus particles |
| 07/20/2006 | WO2006045750A3 T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use |
| 07/20/2006 | WO2006032472A3 Immunogenic composition for use in vaccination against staphylococcei |
| 07/20/2006 | WO2006026404A3 Assay for detecting tuberculosis in nonhuman primates |
| 07/20/2006 | WO2006014985A3 Genetic immunization of transgenic animals with non-eukaryotic expression systems |
| 07/20/2006 | WO2006014726A3 Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| 07/20/2006 | WO2006005706A3 Combination therapy for preventing or treating alzheimer's disease, and kit therefor |
| 07/20/2006 | WO2005120562A3 Structure-based receptor mimics targeted against bacterial superantigen toxins |
| 07/20/2006 | WO2005117983A3 Carrier conjugates of tnf-peptides |
| 07/20/2006 | WO2005115121A3 Adenylyl cyclase antibodies, compositions and uses thereof |
| 07/20/2006 | WO2005070126A3 Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors |
| 07/20/2006 | WO2005023195A3 Treatment of spinal cord injury |
| 07/20/2006 | WO2005016955A3 Nogo receptor antagonists |
| 07/20/2006 | WO2004028352A3 Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| 07/20/2006 | WO2003084467A3 Epitope constructs comprising antigen presenting cell targeting mechanisms |
| 07/20/2006 | US20060161997 Methods for producing human antibodies in SCID mice |
| 07/20/2006 | US20060161996 Process for producing human-origin immunocompetent cell |
| 07/20/2006 | US20060160997 Tumor-associated antigen specific immunoglobulin fusion for use in diagnosis, prevention and treatment of cell proliferative |
| 07/20/2006 | US20060160995 Thrombopoietin proteins with improved properties |
| 07/20/2006 | US20060160992 Method of identifying cells expressing a protein having pre-B cell growth-supporting ability |
| 07/20/2006 | US20060160991 Genes and polypeptides relating to prostate cancers |
| 07/20/2006 | US20060160764 LIMKs as modifiers of p53 pathway and methods of use |
| 07/20/2006 | US20060160762 Methods for the treatment, diagnosis, and prognosis of cancer |
| 07/20/2006 | US20060160723 Glycoproteins having lipid mobilising properties and therapeutic applications thereof |
| 07/20/2006 | US20060160159 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 07/20/2006 | US20060160154 Materials and methods for detection and treatment of breast cancer |
| 07/20/2006 | US20060160147 Recombinant cell line |
| 07/20/2006 | US20060160143 Mitogenic oxygenases |
| 07/20/2006 | US20060160130 Recombinant RSV virus expression systems and vaccines |
| 07/20/2006 | US20060160088 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40) |
| 07/20/2006 | US20060160073 Efficient algorithm for PCR testing of blood samples |
| 07/20/2006 | US20060159769 Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| 07/20/2006 | US20060159710 Pertussis toxin gene:cloning and expression of protective antigen |
| 07/20/2006 | US20060159709 Recombinant high molecular weight major outer membrane protein of moraxella |
| 07/20/2006 | US20060159708 Vascular Leak Syndrome; polypeptide toxophore from a DT; has cytotoxicity comparable to that of a DT molecule |
| 07/20/2006 | US20060159707 Lawsonia derived gene and related FlgE polypeptides, peptides and proteins and their uses |
| 07/20/2006 | US20060159706 Novel insertion sites in pox vectors |
| 07/20/2006 | US20060159705 Purification of HBV antigens for use in vaccines |
| 07/20/2006 | US20060159704 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and other infectious agents |
| 07/20/2006 | US20060159703 Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| 07/20/2006 | US20060159702 non-covalent complex of purified, detoxified lipopolysaccharide endotoxin of escherichia strains and purified outer membrane protein of neisseria, used for inoculation against infections by inducing immunoglobulins specific to escherichia |
| 07/20/2006 | US20060159701 Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| 07/20/2006 | US20060159700 Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation |
| 07/20/2006 | US20060159699 Dengue viruses useful for vaccination against Flavivirus; Modified Vaccinia Virus Ankara (MVA); stable, can easily be produced |
| 07/20/2006 | US20060159697 Modified bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
| 07/20/2006 | US20060159696 Neutralizing epitope-based growth enhancing vaccine |
| 07/20/2006 | US20060159695 Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| 07/20/2006 | US20060159694 Combinations of tumor-associated antigens in compositions for various types of cancers |
| 07/20/2006 | US20060159693 Idiotypic vaccine |
| 07/20/2006 | US20060159692 Transcriptional factor inducing apoptosis in cancer cell |
| 07/20/2006 | US20060159691 Ptprk immunogenic peptide |
| 07/20/2006 | US20060159690 H-Y antigen |
| 07/20/2006 | US20060159689 Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| 07/20/2006 | US20060159688 Measuring the level of a xenotypic antibody produced by a patient after synergistic administration with an anticarcinogenic agent; immunotherapy |
| 07/20/2006 | US20060159687 Modified aerolysin and methods of use for treating lung cancer |
| 07/20/2006 | US20060159686 Natural killer cell activating factor II |
| 07/20/2006 | US20060159685 Of given sequence; immunomodulators; prophylaxis or treatments for cancers |
| 07/20/2006 | US20060159684 Compositions and methods for the threatment of sepsis |
| 07/20/2006 | US20060159683 Stabilization of chimeric immunoglobulin; obtain immunoglobulin, monitor structure, determine sequence, adjust amino acid sequences for greater stability |
| 07/20/2006 | US20060159682 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof |
| 07/20/2006 | US20060159681 Compositions and methods to inhibit cell loss by using inhibitors of BAG |
| 07/20/2006 | US20060159680 Targeted apherisis for the treatment of rheumatoid arthritis |
| 07/20/2006 | US20060159679 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 07/20/2006 | US20060159678 Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy |
| 07/20/2006 | US20060159677 Tumour necrosis factor peptide binding antibodies |
| 07/20/2006 | US20060159676 Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
| 07/20/2006 | US20060159675 Compositions and methods for treating coagulation related disorders |
| 07/20/2006 | US20060159674 Drug screening; modulating amyloid beta -protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein; neurodegenerative diseases |
| 07/20/2006 | US20060159673 Methods of screening light chain of antibody |
| 07/20/2006 | US20060159672 Identification of self and non-self antigens implicated in autoimmune diseases |
| 07/20/2006 | US20060159669 Novel uses of PPAR modulators and professional APCs manipulated by the same |
| 07/20/2006 | US20060159662 Therapeutic anti-melanoma compounds |
| 07/20/2006 | US20060159655 Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor |
| 07/20/2006 | US20060159654 Interacting the immature dendritic cells with an antigen ex vivo so that the surface antigen is presented; inducing maturation ex vivo; and contacting with a modulator comprising TRANCE; an increased viability relative to a control dendritic cell not contacted with TRANCE |
| 07/20/2006 | US20060159653 Stabilized preparation containing protein |
| 07/20/2006 | CA2597698A1 Mycobacterial mutants affecting host apoptosis |
| 07/20/2006 | CA2595128A1 Meningococcal conjugate vaccination |
| 07/20/2006 | CA2594922A1 Monoclonal antibodies that bind or neutralize hepatitis b virus |